- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01840046
Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata (IL2)
Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe Alopecia Areata Resistant to Conventional Systemic Treatment
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, France, 06001
- CHU de Nice - Hôpital Archet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years, 60 ≤ years.
- Male or female
- Clinical diagnosis of alopecia areata,
- Severe alopecia areata (> 50% of the surface of the scalp reached)
- Alopecia areata resistant to at least one systemic therapy: phototherapy (UVB or PUVA), methotrexate or corticosteroids
- Signature of the informed consent and authorization of the right image
- Effective contraception will be maintained for the duration of the study.
- Affiliation to the Social Security
Exclusion Criteria:
- Pregnancy or refusal of contraception in women of childbearing age,
- Refusal of contraception for men
- Local treatment (corticosteroids, minoxidil) or systemic (oral corticosteroids, methotrexate or other immunosuppressive agents) for less than 2 months,
- Cancer or autoimmune disease or in remission evolutionary
- Excessive alcohol intake (more than 3 glasses of wine a day or a drink per day)
- HIV, hepatitis C virus, hepatitis B virus
- Patient with renal and / or hepatic impairment,
- Patient with shingles, chickenpox, herpes, tuberculosis, an infectious disease scalable, respiratory failure ...
- Vulnerable person (anyone younger, adults under guardianship, deprived of liberty)
- Indication against treatment with IL2-R
- Presenting an indication against the Proleukin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interleukin 2
The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule: 5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9. The dosage is as follows: S1: 1.5 mille-International unit (MIU) / day D1 to D5, S3, S6 and S9: 3 mille-International unit /Jour D1 to D5. |
The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule: 5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9. The dosage is as follows: S1: 1.5 mille-International unit / day (D1 to D5), S3, S6 and S9: 3 mille-International unit /Jour (D1 to D5). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients who obtained an improvement of at least 90% of the score validated severity score in alopecia areata in 2 months.
Time Frame: 2 months
|
Number of patients who obtained an improvement of at least 90% of SALT (SALT 90) validated severity score in alopecia areata in 2 months.
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the quality of life
Time Frame: 2 months
|
Number of patients who obtained an improvement of at least 50% of score (SALT 90) validated severity score in alopecia areata in 2 months. Assess the partial response rate. Evaluation of the effects of treatment on body hair and nail achieving. Overall assessment by an independent investigator to regrow after treatment (Physician global assessment): Evaluation of the quality of life before and at the end of treatment. Overall assessment by the patient (patient global assessment) of regrowth. Overall tolerability of treatment. Study population effects of IL2-R on the population of Treg cells in the blood. The effects of IL-2 on the inflammatory infiltrate and the distribution of regulatory T cells in the skin. |
2 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: PASSERON Thierry, PhD, CHU de Nice - Hôpital de l'Archet - Dermatology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-PP-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alopecia Areata
-
Eli Lilly and CompanyRecruitingSkin Diseases | Pathological Conditions, Anatomical | Alopecia | Hypotrichosis | Hair Diseases | Areata AlopeciaUnited States, Taiwan, Japan, Spain, Korea, Republic of, Germany, France, Mexico, Canada, Poland, Australia, Hungary, Argentina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdActive, not recruitingAlopecia Areata(AA)China
-
University Hospital, RouenCompletedALOPECIA AREATAFrance
-
Services Institute of Medical Sciences, PakistanCompletedExtensive Alopecia AreataPakistan
-
Yale UniversityCompletedAlopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Inmagene LLCRecruitingAlopecia Areata (AA)United States, Canada
-
Siriraj HospitalCompletedRecalcitrant Alopecia Totalis | Recalcitrant Alopecia UniversalisThailand
-
EquilliumWithdrawnAlopecia Areata | Alopecia Totalis | Alopecia Universalis
-
Lindsey BordoneWithdrawnAlopecia Areata | Alopecia Totalis | Alopecia Universalis
-
Aclaris Therapeutics, Inc.Completed
Clinical Trials on Interleukin-2
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of Michigan Rogel Cancer CenterUniversity of MichiganTerminated
-
Loma Linda UniversityWithdrawnMelanoma | Metastatic Kidney CancerUnited States
-
City of Hope Medical CenterCompletedGlioblastoma | Brain Tumor | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Giant Cell Glioblastoma | Anaplastic Meningioma | Mixed Glioma | Brain Stem Glioma | Ependymoblastoma | Grade III Meningioma | Meningeal Hemangiopericytoma | Pineal Gland AstrocytomaUnited States
-
Assistance Publique - Hôpitaux de ParisIltoo PharmaActive, not recruitingRecurrent MiscarriageFrance
-
National Heart, Lung, and Blood Institute (NHLBI)Completed
-
National Cancer Institute (NCI)TerminatedRecurrent NeuroblastomaUnited States
-
French National Agency for Research on AIDS and...Chiron CorporationCompleted
-
Icahn School of Medicine at Mount SinaiCompletedCommon Variable Immunodeficiency
-
Aalborg University HospitalUnknownHIV Infections | Hepatitis B | Hepatitis ADenmark